Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, AstraZeneca Pharma India has informed that the Company has received an order from the Income-tax Appellate Tribunal (‘ITAT’) issued under section 254 of the Income Tax Act, 1961 for the assessment year 2017-18 and 2018-19 on December 3, 2024. In this regard, the company has enclosed the details as required under the SEBI Circular SEBI/HO/CFD/CFDPoD-1/P/CIR/2023/123 dated July 13, 2023 attached as Annexure – A.
The above information is a part of company’s filings submitted to BSE.
